Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
How Multiplex CRISPR Changes Genome Interpretation
2026-11-16
Multiplex CRISPR–Cas systems are powerful because they connect programmable DNA targeting with the cell’s own repair pathways. The same mechanism that enables coordinated gene disruption and structural-variant modeling also creates interpretive challenges: phenotypes may reflect intended gene perturbation, cumulative DNA damage, unintended edits, or interactions among targets.
Multiplexed CRISPR–Cas: Reading the Evidence
2026-11-16
A literature-focused analysis of how multiplexed CRISPR–Cas systems extend genome editing from single-locus perturbation to coordinated gene disruption, structural-variant modeling, epigenetic regulation and multi-damage cell studies. It separates established mechanistic principles from emerging claims about delivery, specificity and AI-designed editors.
Multiplex CRISPR: From DNA Breaks to Cell Fate
2026-11-15
Multiplex CRISPR links guide-RNA-directed DNA damage to gene disruption, structural variation, coordinated transcriptional control and, in some contexts, selective cell loss. The strongest evidence supports mechanistic feasibility, while quantitative performance, specificity and applicability remain dependent on the editing architecture and cellular model.
NHE1 and Octanal in Macrophage Atherosclerosis
2026-11-14
A mouse and macrophage study links octanal–Olfr2 signaling to NHE1 activation, calcium elevation, oxidative stress, inflammasome-associated inflammation, foam-cell formation, and plaque progression. The evidence supports NHE1 as a mechanistic downstream effector in the tested models, while leaving important questions about pathway ordering, pharmacological specificity, and relevance to human disease.
When Context Changes What a CRISPR Result Means
2026-11-13
A CRISPR outcome can signify a molecular edit, a structural rearrangement, altered gene regulation, or cell selection depending on the model, target architecture, delivery context, and readout. This editorial examines how those contexts constrain interpretation of multiplex genome-editing findings.
When Context Changes What CRISPR Results Mean
2026-11-13
A genome-editing result does not have a fixed meaning outside its model, perturbation design, readout, and delivery context. This editorial examines how the same CRISPR platform can support different claims about molecular editing, structural variation, gene function, cell viability, and translational feasibility.
What Multiplex CRISPR Evidence Shows
2026-11-12
A literature-focused analysis of how multiplexed CRISPR–Cas systems enable simultaneous gene perturbation, structural-variant modeling, epigenome editing and combinatorial functional screens. The review supports a strong mechanistic case for multiplexing while emphasizing unresolved problems in specificity, delivery, cellular damage and clinical transferability.
What Multiplex CRISPR Evidence Actually Shows
2026-11-12
Published comparisons support multiplex CRISPR as a flexible framework for coordinated gene disruption, structural-variant modeling and transcriptional regulation, but they do not establish a universal advantage across cell types or readouts. The strongest unresolved issues are cumulative off-target damage, delivery constraints, tradeoffs between specificity and activity, and the limited basis for extrapolating broad human-cell findings to any particular cell-line preparation.
Multiplex CRISPR: What the Evidence Shows
2026-11-11
Multiplex CRISPR can generate coordinated genetic perturbations, including deletions and other structural variants, but the same DNA-damage burden that enables these outcomes can confound functional interpretation. The strongest evidence supports technical feasibility; claims about specificity, therapeutic selectivity, or performance in any particular cell preparation require narrower, primary-study evidence.
What Multiplex CRISPR Evidence Actually Shows
2026-11-11
A literature-focused analysis of how multiplexed CRISPR–Cas editing expands genetic perturbation while increasing interpretive, delivery and safety challenges. The evidence supports feasibility across several editing modes, but does not justify treating multiplex editing as uniformly precise, clinically transferable or functionally complete.
What Multiplex CRISPR Evidence Actually Shows
2026-11-10
A 2025 highlight/review explains why multiplex CRISPR–Cas systems can expose genetic interactions, create defined structural variants, and regulate several loci at once. Its evidence also shows why broader targeting increases interpretive and safety challenges: DNA-damage responses, off-target activity, delivery constraints, and heterogeneous repair can complicate causal conclusions. The strongest lesson is not simply that multiplex editing is powerful, but that each readout must be interpreted in the context of the editing mechanism that produced it.
SIRT1, Type H Vessels, and Bone Repair
2026-11-10
Recent work links reduced SIRT1 activity with age-related loss of type H vessels and impaired osteogenesis. In aged mouse models and senescent cell systems, pharmacological SIRT1 activation improved vascular, cellular, and structural bone readouts through a proposed β-catenin–Wnt mechanism, while important questions about specificity, translation, and functional bone strength remain.
What Multiplex CRISPR Editing Can—and Cannot—Show
2026-11-09
Multiplex CRISPR–Cas systems extend genome engineering from single-locus perturbation to coordinated changes across genes, regulatory elements and chromosome structures. This editorial examines the mechanistic logic, evidence layers and translational limitations synthesized in a 2025 review, while distinguishing demonstrated molecular outcomes from broader therapeutic interpretation.
Multiplex CRISPR: Promise, Mechanism and Trade-offs
2026-11-09
A critical guide to how multiplexed CRISPR expands genome perturbation, what the cited review reports about structural variation and functional screening, and why specificity, delivery, repair outcomes and model context limit interpretation.
What Multiplex CRISPR Editing Actually Shows
2026-11-08
Multiplex CRISPR editing can expose gene interactions and generate large genomic rearrangements, but the same DNA-damage mechanism that enables these outcomes complicates causal interpretation. Evidence reviewed in 2025 supports broad utility across human cell models while highlighting unresolved questions about structural variants, off-target activity, delivery, and model-specific effects.